EGFR T790M Mutation in Circulating Tumor DNA by Digital Droplet PCR

EGFR T790M Mutation in Circulating Tumor DNA by Digital Droplet PCR

ctDNA testing provides a rapid, minimally invasive blood testing alternative to traditional biopsy or resection tissue analysis of EGFR T790M mutation status in non-small cell lung adenocarcinoma.

This test is ideally suited for testing blood plasma or cerebrospinal fluid for:
  • EGFR T790M drug-resistant mutation detection at initial diagnosis or recurrence of non-small cell lung adenocarcinoma.
  • Quantitative, highly-sensitive (0.5–
    < 0.01% mutant allele frequency*) monitoring of therapeutic response or disease progression in patients eligible for EGFR T790M-specific TKIs.
    * based upon the amount of amplification DNA, the limit of detection ranges from 0.5% to less than 0.01% mutant alleles.

Typical Testing Strategy

In patients with EGFR gene mutations who are treated with early-generation TKIs, consider monitoring for development of an acquired EGFR T790M mutation.

  • Blood plasma
    • Serial quantitative testing
      • Guides clinical treatment decisions about acquired resistance to early-generation TKIs and decision to switch to EGFR T790M-specific TKIs.
      • Monitors response to therapy in patients taking EGFR T790M-specific TKIs.
  • Cerebrospinal fluid
    • Serial quantitative testing for patients with isolated NSCLC brain metastases and undetectable blood plasma levels of EGFR T790M mutation.
    • Guides clinical treatment decisions about switching to EGFR T790M-specific TKIs.
    • Monitors response to therapy.

Additional Resources